Safety and Tolerability of Burst Cycling Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease
Objective: To determine the safety and tolerability of burst cycling deep brain stimulation (DBS) in Parkinson's disease (PD) patients experiencing freezing of gait (FoG). Background:…Improvement for Gait Disorders in Parkinson’s Disease Through Novel Comprehensive Treatment (IMPROVE study): A Prospective, Open-label, Randomized Controlled Clinical Trial
Objective: We conducted a prospective, open-label, randomized controlled clinical trial (clinical trial identifier: ChiCTR1900023466) to evaluate the effects of different combinations of comprehensive treatment on…The Association of Taichi to Delayed Progression of Parkinson’s Disease
Objective: To discover the effect of physical exercise on motor and non-motor symptoms in Parkinson’s disease (PD), and to explore whether physical exercise could delay…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Exploratory fluid-based biomarker endpoints of the 12-month treatment period
Objective: To explore fluid-based biomarkers in subjects with advanced idiopathic Parkinson’s disease (PD) before and after intermittent intraputamenal monthly infusions of CDNF. Background: CDNF is…Impact of safinamide on non-motor and motor experiences of daily living: Primary results from the prospective, observational ProGo study
Objective: Evaluate the effect of safinamide treatment on non-motor and motor experiences of daily living as assessed using the MDS-UPDRS (Parts I nm-EDLand II m-EDL).…Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…Reduction of OFF time with apomorphine infusion during hours of pump use: Analysis from a Phase III, open-label study
Objective: Evaluate the efficacy of apomorphine (APO) infusion in reducing OFF time during the hours of pump use in PD patients with motor fluctuations inadequately…The exosomal a-syn filaments can be a novel biomarker of Parkinson’s disease
Objective: This study is aimed to investigate whether the number of exosomes, the amount of total or exosomal a-synuclein (a-syn) filaments in serum can serve as…Comparison of Categorical- and Verbatim-Reported Postural Instability Symptoms Among Fox Insight Parkinson Research Participants
Objective: To analyze verbatim patient-reported problems compared with ordinal measures referable to Postural Instability (PI) symptoms in the Fox Insight (FI) observational study. Background: FI…Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations
Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.